MDPV: Difference between revisions

Line 16:

==Pharmacology==

MDPV ~~acts~~ primarily as a potent [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[catecholamine]] [[neurotransmitter]]s in the [[Synapse|synaptic cleft]], or gap between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged concentration and resulting post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] also plays a role, although to a much lesser degree. This sudden increase in neurotransmitter concentration in the brain is thought to be responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] or [[methylphenidate]] than [[amphetamine]] in method of action.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> In contrast, amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.

MDPV is thought to act primarily as a potent [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[catecholamine]] [[neurotransmitter]]s in the [[Synapse|synaptic cleft]], or gap between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged concentration and resulting post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] also plays a role, although to a much lesser degree. This sudden increase in neurotransmitter concentration in the brain is thought to be responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] or [[methylphenidate]] than [[amphetamine]] in method of action.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> In contrast, amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.

==Subjective effects==

@@ Line 16: / Line 16: @@
 ==Pharmacology==
-MDPV acts primarily as a potent [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[catecholamine]] [[neurotransmitter]]s in the [[Synapse|synaptic cleft]], or gap between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged concentration and resulting post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] also plays a role, although to a much lesser degree. This sudden increase in neurotransmitter concentration in the brain is thought to be responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] or [[methylphenidate]] than [[amphetamine]] in method of action.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> In contrast, amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.
+MDPV is thought to act primarily as a potent [[Noradrenaline|norepinephrine]]-[[dopamine]] [[reuptake inhibitor]]. Reduced re-uptake of norepinephrine and dopamine results in higher concentrations of the two [[catecholamine]] [[neurotransmitter]]s in the [[Synapse|synaptic cleft]], or gap between [[Neurons|neurons]]. The result of this inhibition is an enhanced and prolonged concentration and resulting post-synaptic effect of dopaminergic and noradrenaline signaling at dopamine and norepinephrine receptors on the receiving neuron. [[Serotonin]] also plays a role, although to a much lesser degree. This sudden increase in neurotransmitter concentration in the brain is thought to be responsible for the high that MDPV provides. Mainly possessing re-uptake inhibiting qualities, MDPV could be considered more like [[cocaine]] or [[methylphenidate]] than [[amphetamine]] in method of action.<ref>http://www.who.int/medicines/areas/quality_safety/4_13_Review.pdf?ua=1</ref> In contrast, amphetamine acts primarily as an agonist to release dopamine and noradrenaline indirectly via activation of the TAAR1 receptor.
 ==Subjective effects==